title: Cyclical and dose-dependent responses of adult human mature oligodendrocytes to fingolimod.
abstract: Fingolimod is a sphingosine-1-phosphate (S1P) analogue that has been used in clinical trials as a systemic immunomodulatory therapy for multiple sclerosis. Fingolimod readily accesses the central nervous system, raising the issue of its direct effects on neural cells. We assessed the effects of active fingolimod on dissociated cultures of mature, myelin-producing oligodendrocytes (OLGs) derived from adult human brain. Human OLGs express S1P receptor transcripts in relative abundance of S1P5>S1P3>S1P1, with undetectable levels of S1P4. Low doses of fingolimod (100 pmol/L to 1 nmol/L) induced initial membrane elaboration (2 days), subsequent retraction (4 days), and recurrence of extension with prolonged treatment (8 days). Higher doses (10 nmol/L to 1 mumol/L) caused the opposite modulation of membrane dynamics. Retraction was rescued by co-treatment with the S1P3/S1P5 pathway antagonist, suramin, and was associated with RhoA-mediated cytoskeletal signaling. Membrane elaboration was mimicked using the S1P1 agonist SEW2871. Fingolimod rescued human OLGs from serum and glucose deprivation-induced apoptosis, which was reversed with suramin co-treatment and mimicked using an S1P5 agonist. High doses of fingolimod induced an initial down-regulation of S1P5 mRNA levels relative to control (4 hours), subsequent up-regulation (2 days), and recurrent down-regulation (8 days). S1P1 mRNA levels were inversely regulated compared with S1P5. These results indicate that fingolimod modulates maturity- and species-specific OLG membrane dynamics and survival responses that are directly relevant for myelin integrity.
authors.affiliation: Neuroimmunology Unit, Montreal Neurological Institute, McGill University, Montreal, QC, Canada.
authors.forename: Veronique E
authors.initials: VE
authors.lastname: Miron
authors.forename: Jeffery A
authors.initials: JA
authors.lastname: Hall
authors.forename: Timothy E
authors.initials: TE
authors.lastname: Kennedy
authors.forename: Betty
authors.initials: B
authors.lastname: Soliven
authors.forename: Jack P
authors.initials: JP
authors.lastname: Antel
mesh_terms: D000328:Adult; D017209:Apoptosis / Q000187:drug effects; D002454:Cell Differentiation / Q000187:drug effects*; D002470:Cell Survival / Q000187:drug effects; D003599:Cytoskeleton / Q000187:drug effects / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D000068876:Fingolimod Hydrochloride; D005786:Gene Expression Regulation / Q000187:drug effects; D005947:Glucose / Q000172:deficiency; D006801:Humans; D009836:Oligodendroglia / Q000166:cytology* / Q000187:drug effects* / Q000378:metabolism; D011409:Propylene Glycols / Q000494:pharmacology*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D049349:Receptors, Lysosphingolipid / Q000235:genetics / Q000378:metabolism; D044967:Serum; D013110:Sphingosine / Q000031:analogs & derivatives* / Q000494:pharmacology; D013997:Time Factors
chemical_list: D011409:Propylene Glycols; D012333:RNA, Messenger; D049349:Receptors, Lysosphingolipid; D000068876:Fingolimod Hydrochloride; D005947:Glucose; D013110:Sphingosine
references.citation: J Neuroimmunol. 2004 Aug;153(1-2):108-21
references.pmid: 15265669
references.citation: Transplant Proc. 2005 Jan-Feb;37(1):107-9
references.pmid: 15808562
references.citation: Neuron. 1997 Jul;19(1):197-203
references.pmid: 9247275
references.citation: Biochem J. 1977 May 15;164(2):323-9
references.pmid: 880240
references.citation: Biochem Pharmacol. 2002 Oct 15;64(8):1243-50
references.pmid: 12234605
references.citation: J Immunol. 2005 Oct 1;175(7):4320-30
references.pmid: 16177072
references.citation: Glia. 2007 Jan 15;55(2):130-43
references.pmid: 17078030
references.citation: J Neurosci. 2005 Feb 9;25(6):1459-69
references.pmid: 15703400
references.citation: Am J Transplant. 2005 Nov;5(11):2649-59
references.pmid: 16212624
references.citation: J Neurochem. 2006 Mar;96(6):1616-25
references.pmid: 16441511
references.citation: N Engl J Med. 2006 Sep 14;355(11):1124-40
references.pmid: 16971719
references.citation: Nat Rev Neurosci. 2002 Sep;3(9):705-14
references.pmid: 12209119
references.citation: Glia. 2007 Dec;55(16):1656-67
references.pmid: 17876806
references.citation: J Biol Chem. 2003 Nov 28;278(48):47408-15
references.pmid: 13129923
references.citation: Ann Neurol. 2008 Jan;63(1):61-71
references.pmid: 17918267
references.citation: Mol Biol Cell. 1999 Apr;10(4):1179-90
references.pmid: 10198065
references.citation: Neuroscience. 2003;116(4):1053-62
references.pmid: 12617946
references.citation: FASEB J. 2004 Mar;18(3):551-3
references.pmid: 14715694
references.citation: Brain. 2004 Dec;127(Pt 12):2636-48
references.pmid: 15509624
references.citation: Br J Pharmacol. 2003 Feb;138(3):481-93
references.pmid: 12569073
references.citation: Biochim Biophys Acta. 1968 Oct 22;164(2):285-93
references.pmid: 4305490
references.citation: J Pharmacol Exp Ther. 2007 Nov;323(2):469-75
references.pmid: 17682127
references.citation: J Neurochem. 2003 Nov;87(4):947-57
references.pmid: 14622125
references.citation: Nat Rev Neurosci. 2005 Sep;6(9):683-90
references.pmid: 16136172
references.citation: Acta Neuropathol. 1984;64(2):172-5
references.pmid: 6475502
references.citation: Ann N Y Acad Sci. 2000 Apr;905:118-31
references.pmid: 10818448
references.citation: J Biol Chem. 1999 Jul 2;274(27):18997-9002
references.pmid: 10383399
references.citation: J Cell Biol. 2004 Aug 2;166(3):381-92
references.pmid: 15289497
references.citation: Blood. 2003 Jun 15;101(12):4909-15
references.pmid: 12586615
references.citation: J Cell Biochem. 2004 Aug 1;92(5):913-22
references.pmid: 15258915
references.citation: J Clin Invest. 2004 Dec;114(11):1531-7
references.pmid: 15578083
references.citation: J Exp Med. 1996 Dec 1;184(6):2361-70
references.pmid: 8976190
references.citation: J Immunol. 2005 Dec 15;175(12):7973-80
references.pmid: 16339533
references.citation: Biochem J. 1974 Apr;140(1):99-109
references.pmid: 4141622
references.citation: Glia. 2004 Jan 1;45(1):17-27
references.pmid: 14648542
references.citation: Curr Opin Neurobiol. 2007 Oct;17(5):533-40
references.pmid: 17923405
references.citation: Neuroscientist. 2007 Oct;13(5):486-91
references.pmid: 17901257
references.citation: Science. 2002 Apr 12;296(5566):346-9
references.pmid: 11923495
references.citation: FASEB J. 2007 May;21(7):1503-14
references.pmid: 17255471
references.citation: Brain Pathol. 2007 Apr;17(2):210-8
references.pmid: 17388952
references.citation: Nature. 2004 Jan 22;427(6972):355-60
references.pmid: 14737169
references.citation: Braz J Med Biol Res. 2005 May;38(5):683-94
references.pmid: 15917949
references.citation: Trends Mol Med. 2006 Feb;12(2):65-75
references.pmid: 16406843
references.citation: J Biol Chem. 2005 Mar 18;280(11):9833-41
references.pmid: 15590668
references.citation: J Biol Chem. 2007 Feb 16;282(7):4310-4317
references.pmid: 17166850
references.citation: J Immunol. 2002 Oct 15;169(8):4084-7
references.pmid: 12370333
references.citation: J Pharmacol Exp Ther. 2007 Nov;323(2):626-35
references.pmid: 17726159